Skip to main content
Jens Lohr, MD, Oncology, Boston, MA

Jens G Lohr MD


Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Join to View Full Profile
  • 44 Binney StMedical Oncology, Dfci, Smith 353Boston, MA 02115

  • Phone+1 617-632-3485

Are you Dr. Lohr?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Jens Lohr, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Utah, and California. He is a Clinical Fellow in Medicine at Dana-Farber Cancer Institute.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2006 - 2008
  • Ruprecht Karl University Faculty of Medicine
    Ruprecht Karl University Faculty of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2009 - 2026
  • UT State Medical License
    UT State Medical License 2024 - 2026
  • MA State Medical License
    MA State Medical License 2010 - 2025
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • American Thyroid Association Awards ThyCa Research Grant to Jens Lohr, MD, PhD, Dana Farber Cancer Institute
    American Thyroid Association Awards ThyCa Research Grant to Jens Lohr, MD, PhD, Dana Farber Cancer InstituteAugust 9th, 2017

Grant Support

  • Liquid biopsy in myeloma to inform outcome and treatment decisionsDANA-FARBER CANCER INST2023–2027